葛根素联合羟苯磺酸钙治疗糖尿病视网膜病变的疗效分析(1)
[摘要] 目的 分析葛根素联合羟苯磺酸钙在治疗糖尿病视网膜病变方面的疗效。方法 选择该院2016年1—12月所收治的76例糖尿病视网膜病变患者作为该次研究的对象，将其随机分为观察组与对照组，每组38例。对照组单纯采用羟苯磺酸钙进行治疗，观察组在此基础上联用葛根素，在为期1个月的治疗周期后，比较两组患者的临床疗效，分析治疗方案的临床价值。 结果 该次研究结果表明，观察组在治疗有效率上以94.7%显著优于对照组的81.6%，证明了葛根素在治疗过程中的使用价值。数据差异有统计学意义(χ2=3.856，P=0.013)。 结论 葛根素联合羟苯磺酸钙在治疗糖尿病视网膜病变方面效果显著，同时也能保障治疗的安全稳定性，可以在今后作为主流治疗方案。
[关键词] 葛根素;羟苯磺酸钙;糖尿病视网膜病变;疗效分析
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2019)04(b)-0185-02
[Abstract] Objective To analyze the efficacy of puerarin combined with calcium hydroxybenzenesulfonate in the treatment of diabetic retinopathy. Methods 76 patients with diabetic retinopathy admitted to our hospital from January to December 2016 were enrolled in this study. They were randomly divided into observation group and control group， with 38 cases in each group. The control group was treated with calcium hydroxybenzenesulfonate alone. The observation group was combined with puerarin. After a one-month treatment cycle， the clinical efficacy of the two groups was compared and the clinical value of the treatment plan was analyzed. Results The results of this study showed that the effective rate of the observation group was significantly higher than that of the control group (94.7% vs 81.6%)， which proved the use value of puerarin in the treatment process. The data were significantly different and statistically significant (χ2=3.856，P=0.013). Conclusion Puerarin combined with calcium dobesilate is effective in the treatment of diabetic retinopathy， and it can also guarantee the safety and stability of treatment. It can be used as a mainstream treatment in the future.
[Key words] Puerarin; Calcium dobesilate; Diabetic retinopathy; Efficacy analysis
糖尿病視网膜病变是糖尿病微血管病变中的典型表现，也是一种具有特异性的眼底病变。患者病因通常是因为胰岛素代谢异常引起的微循环改变，临床表现一般为出血动脉瘤、出血斑点等。一般情况下，药物治疗是一种稳定的治疗方案，包括阿司匹林、羟苯磺酸钙等药物、光凝治疗、冷凝治疗等。在近年来的研究当中，针对中医治疗提出了各种方案，因此该文也旨在探讨葛根素在糖尿病视网膜病变方面的临床疗效，统计了2016年1—12月76例患者资料展开回顾性分析，现报道如下。
1 资料与方法
1.1 一般资料
选择该院所收治的76例糖尿病视网膜病变患者作为该次研究的对象，将其随机分为观察组与对照组，每组38例。观察组中男性22例，女性16例，年龄33～68岁，平均年龄(50.3±2.5)岁，糖尿病病程1～13年，平均时间(6.0±1.0)年;观察组中男性23例，女性15例，年龄35～68岁，平均年龄(50.4±2.7)岁，糖尿病病程1～14年，平均时间(6.1±1.2)年。
纳入标准：所有患者经过眼底检查和荧光血管造影后确定为视网膜病变情况，且所有患者具有糖尿病病史。
排除标准：患者伴有肝肾功能疾病、感染性疾病;孕产妇;精神疾病患者。
研究经过伦理委员会批准，并且经过患者与家属同意后签署自愿同意书后展开。所有患者在性别、年龄等一般数据资料的对比差异无统计学意义(P>0.05)，具有可比性。, 百拇医药(吴俊生)
[关键词] 葛根素;羟苯磺酸钙;糖尿病视网膜病变;疗效分析
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2019)04(b)-0185-02
[Abstract] Objective To analyze the efficacy of puerarin combined with calcium hydroxybenzenesulfonate in the treatment of diabetic retinopathy. Methods 76 patients with diabetic retinopathy admitted to our hospital from January to December 2016 were enrolled in this study. They were randomly divided into observation group and control group， with 38 cases in each group. The control group was treated with calcium hydroxybenzenesulfonate alone. The observation group was combined with puerarin. After a one-month treatment cycle， the clinical efficacy of the two groups was compared and the clinical value of the treatment plan was analyzed. Results The results of this study showed that the effective rate of the observation group was significantly higher than that of the control group (94.7% vs 81.6%)， which proved the use value of puerarin in the treatment process. The data were significantly different and statistically significant (χ2=3.856，P=0.013). Conclusion Puerarin combined with calcium dobesilate is effective in the treatment of diabetic retinopathy， and it can also guarantee the safety and stability of treatment. It can be used as a mainstream treatment in the future.
[Key words] Puerarin; Calcium dobesilate; Diabetic retinopathy; Efficacy analysis
糖尿病視网膜病变是糖尿病微血管病变中的典型表现，也是一种具有特异性的眼底病变。患者病因通常是因为胰岛素代谢异常引起的微循环改变，临床表现一般为出血动脉瘤、出血斑点等。一般情况下，药物治疗是一种稳定的治疗方案，包括阿司匹林、羟苯磺酸钙等药物、光凝治疗、冷凝治疗等。在近年来的研究当中，针对中医治疗提出了各种方案，因此该文也旨在探讨葛根素在糖尿病视网膜病变方面的临床疗效，统计了2016年1—12月76例患者资料展开回顾性分析，现报道如下。
1 资料与方法
1.1 一般资料
选择该院所收治的76例糖尿病视网膜病变患者作为该次研究的对象，将其随机分为观察组与对照组，每组38例。观察组中男性22例，女性16例，年龄33～68岁，平均年龄(50.3±2.5)岁，糖尿病病程1～13年，平均时间(6.0±1.0)年;观察组中男性23例，女性15例，年龄35～68岁，平均年龄(50.4±2.7)岁，糖尿病病程1～14年，平均时间(6.1±1.2)年。
纳入标准：所有患者经过眼底检查和荧光血管造影后确定为视网膜病变情况，且所有患者具有糖尿病病史。
排除标准：患者伴有肝肾功能疾病、感染性疾病;孕产妇;精神疾病患者。
研究经过伦理委员会批准，并且经过患者与家属同意后签署自愿同意书后展开。所有患者在性别、年龄等一般数据资料的对比差异无统计学意义(P>0.05)，具有可比性。, 百拇医药(吴俊生)